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At comparing treatment efficacy it was established that thyroid gland pa-
thology has a negative impact on the recovery process. Meanwhile the clinical 
symptoms disappearance, conversion of MBT and the healing of cavities were 
faster in patients who had no thyroid pathology. However, these data are frag-
mented, not systematized, and require further study. 
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At present, the use of nebulized inhalation of antimicrobial preparations is 
an effective method of pneumonia treatment. Inhalation therapy, especially in 
severe infiltrative processes in the lungs, let the effective delivery of drugs, 
having variety effects: anti-inflammatory, bronchodilatory, antibacterial and 
mucolytic, both conventional and high doses. A significant advantage of aero-
sol therapy is a high concentration of drugs in air ways at medications insignifi-
cant number itself, and low drug concentration in the organism as a whole. 
Domestic medicine decamethoxin — Dekasan ("YURI-FARM") has a high 
bactericidal activity against gram-positive and Gram-negative, atypical and 
anaerobic bacteria; virusocidal effect on the lipophylic viruses; fungicidal ac-
tion on various types of fungi and antiprotozoal activity (Trichomonas, Giar-
dia). The treatment increases the sensitivity of Dekasan to antibiotic-resistant 
microorganisms to antibiotics. In addition, Dekasan has antispasmodic, 
hyposensencitiz, immunostimulant action, suppresses production of serotonin, 
providing anti-inflammatory and decongestant effects. 
25 patients with community acquired pneumonia have been treated on the 
base of Pulmonology Chernivtsi Regional Hospital, who received the basic 
treatment (antibiotics, mucolytics, detoxication therapy) as well as Dekasan 
inhalation. 5 ml of a 0,02% Dekasan solution at room temperature via a com-
pression nebulizer was used twice a day for 7 days for inhalation. After the 
treatment status patients has improved significantly: in 2-3 days the intensity 
and duration of cough have decreased as well as shortness of breath, sputum 
has become mucous character, the body temperature normalized, symptoms of 
intoxication have decreased. In patients with non-productive cough in 3-4 days 
the frequency and intensity of coughing have decreased. The obtained data al-
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lowed to elaborate effective treatment regimen of patients with diseases of the 
respiratory system, namely pneumonia, by the inclusion nebulized Dekasan in 
the complex treatment. 
Thus, aerosol inhalation therapy with antimicrobial medication Dekasan is 
one of effective methods of treatment community acquired pneumonia, which 
increases the treatment efficacy and reduces the time of clinical recovery such 
patients. 
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The epidemic situation with HIV-infection/AIDS remains a topical problem 
of nowadays both in the world and in Ukraine. Ukraine ranks first in Europe as 
to the  rates of prevalence of  HIV/AIDS. The dynamics of registering new cas-
es of HIV-infected persons in Ukraine over the last 10 years has increased by 
149,5% or 2,5 times (from 17,5 per 100 thousand of the population in 1999 to 
43,2 per 100 thousand of the population in 2009). The AIDS sickness rate has 
increased by 246,4% or 3,5 times (from 2,8 per 100 thousand of the population 
in 2002 to 9,7 in 2009). The tendency of the death rate is similar, it has grown 
in patients with AIDS by 229,4% or 3,3 times (from 1,7 in 2002 to 5,6 per 100 
thousand of the population in 2009). 
The risk of the development of the tuberculosis (TB) disease in HIV-
negative persons during the lifetime makes up to 10, with the highest hazard of 
the development of the clinical form of tuberculosis during the first two years 
following infecting with mycobacteria (MBT). However, in people, living with 
HIV/AIDS without being treated, the risk increases by 5-10% in the year after 
being infected, resulting in general risk during the lifetime — 50%. 
To-date, there is a number of problems that are associated with comorbid 
pathology: 
1. Incomplete coverage with antiretroviral therapy (ART) of all HIV-
infected persons, requiring it. 
2. Partial laboratory monitoring of the course of HIV-infection. 
